Human Immunoglobulin (pH4) for Intravenous Injection Market, By Type (IgG, IgA, and IgM), By Disease Indication (COVID-19, Primary Immunodeficiency Disease, Immune-mediated Thrombocytopenia, Kawasaki Disease, B Chronic lymphocytic Leukemia(B-CLL), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jun 2023

Code : CMI3790

Pages :201

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Human Immunoglobulin Ph4 For Intravenous Injection Market : Key Developments

In July 2022, Takeda Pharmaceutical Company Limited- a Japan-based multinational pharmaceutical company, announced positive results from phase 3 clinical trial evaluating HYQVIA (Immune Globulin Infusion 10% IVIG with Recombinant Human Hyaluronidase) for maintenance treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

According to an article published in October 2022, in PubMed- a medical database for doctors and healthcare professionals, a 16-week trial conducted in dermatomyocitis patients in 2022 showed that IVIG enabled better improvement in disease condition in comparison to placebo.

In May 2020, The Food and Drug Administration (FDA) approved Octapharma Brasil Ltd a- a Switzerland-based pharmaceutical company’s Investigational New Drug Application (IND) allowing the company to initiate a phase 3 trial of Octagam (immune globulin intravenous [human]) in patients with severe coronavirus disease progression.

Global Human Immunoglobulin Ph4 For Intravenous Injection Market: Key Trends

In April 2020, Kamada Pharmaceuticals- a global biopharmaceutical company, and Kedrion S.p.A- a company that develops and distributes plasma-derived medicinal products, partnered to develop, manufacture and distribute a human plasma-derived polyclonal immunoglobulin (IgG) product for potential COVID-19 treatment. Under the collaboration, Kedrion S.p.A will collect and provide plasma at its KEDPLASMA centers from recovered Covid-19 patients. Kamada will carry out product development, manufacturing, and clinical development, in collaboration with Kedrion S.p.A.

In November 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab by Lilly- a U.S.-based pharmaceutical company, for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Bamlanivimab is a monoclonal antibody that is specifically directed against the spike protein of SARS-CoV-2, designed to block the virus’ attachment and entry into human cells.